Highlights on Atopic Dermatitis

Share

Program Content

Activities

  • New Data in AD
    My Take on the Most Clinically Relevant New Data in Atopic Dermatitis
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 10, 2020

    Expires: August 09, 2021

  • Selective JAK Inhibitors for AD
    Selective JAK Inhibitors for Atopic Dermatitis: Important Additions to the Treatment Toolbox
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 12, 2020

    Expires: August 11, 2021

  • Atopic Dermatitis Highlights
    Research Highlights on Atopic Dermatitis: Practice-Changing Results from Recent Clinical Trials
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 21, 2020

    Expires: September 20, 2021

  • Atopic Dermatitis Highlights
    Research Highlights on Atopic Dermatitis: Practice-Changing Results From Recent Clinical Trials
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 05, 2020

    Expires: November 04, 2021

Activities

LIBERTY AD PEDS Results
LIBERTY AD PEDS Study Results: Efficacy and Safety of Dupilumab in Children Aged ≥ 6 to < 12 Yrs With Severe Atopic Dermatitis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 20, 2020

Expires: July 19, 2021

JADE MONO-2 Results
JADE MONO-2 Study Results: Efficacy and Safety of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 20, 2020

Expires: July 19, 2021

Upadacitinib Treatment Withdrawal and Retreatment
Efficacy and Safety of Treatment Withdrawal and Retreatment With Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2020

Expires: July 26, 2021

BREEZE-AD1/2 Pooled Data Results
Pooled Data From BREEZE-AD1 and BREEZE-AD2 Examining the Efficacy and Safety of Baricitinib in Patients With Atopic Dermatitis and Atopic Comorbidities
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2020

Expires: July 26, 2021

Dupilumab for Erythrodermic AD
Dupilumab for Erythrodermic AD: Results From a Pooled Subgroup Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2020

Expires: July 26, 2021

BREEZE-AD5 Results
BREEZE-AD5 Study Results: Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 11, 2020

Expires: August 10, 2021

Faculty

cover img faculity

Andrew F. Alexis, MD, MPH

Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
Director, Skin of Color Center
Mount Sinai West and Mount Sinai Morningside
New York, New York

cover img faculity

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Provided by

ProCE Banner

Supporters

AbbVie Inc.

Pfizer, Inc.